Bruker Corporation (NASDAQ:BRKR) Receives Average Rating of “Hold” from Analysts

Shares of Bruker Corporation (NASDAQ:BRKRGet Free Report) have received an average recommendation of “Hold” from the ten analysts that are currently covering the firm, Marketbeat reports. Six analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $56.22.

Several research firms have recently weighed in on BRKR. Citigroup downgraded shares of Bruker from a “strong-buy” rating to a “hold” rating and decreased their price target for the stock from $50.00 to $40.00 in a research note on Thursday, May 22nd. Stifel Nicolaus decreased their price target on shares of Bruker from $57.00 to $48.00 and set a “hold” rating on the stock in a research note on Thursday, May 8th. Barclays decreased their price target on shares of Bruker from $50.00 to $46.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. UBS Group reduced their target price on shares of Bruker from $57.00 to $45.00 and set a “neutral” rating on the stock in a research note on Thursday, May 8th. Finally, Wells Fargo & Company reduced their target price on shares of Bruker from $75.00 to $60.00 and set an “overweight” rating on the stock in a research note on Thursday, April 17th.

Check Out Our Latest Stock Report on Bruker

Insiders Place Their Bets

In related news, CEO Frank H. Laukien purchased 2,608 shares of the company’s stock in a transaction on Friday, June 6th. The stock was acquired at an average cost of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the transaction, the chief executive officer now directly owns 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. The trade was a 0.01% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 27.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Bruker

Institutional investors have recently made changes to their positions in the stock. Sterling Capital Management LLC increased its position in shares of Bruker by 29.0% during the fourth quarter. Sterling Capital Management LLC now owns 3,514 shares of the medical research company’s stock valued at $206,000 after acquiring an additional 791 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Bruker by 7.6% during the fourth quarter. Bank of New York Mellon Corp now owns 988,863 shares of the medical research company’s stock valued at $57,967,000 after acquiring an additional 69,806 shares during the last quarter. UMB Bank n.a. increased its position in shares of Bruker by 45.8% during the first quarter. UMB Bank n.a. now owns 1,325 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 416 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Bruker by 95.1% during the fourth quarter. Wells Fargo & Company MN now owns 190,855 shares of the medical research company’s stock valued at $11,188,000 after acquiring an additional 93,048 shares during the last quarter. Finally, HighTower Advisors LLC increased its position in shares of Bruker by 6.8% during the fourth quarter. HighTower Advisors LLC now owns 6,972 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 444 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Performance

NASDAQ:BRKR opened at $38.08 on Friday. The company’s 50-day moving average price is $38.23 and its 200-day moving average price is $47.24. The company has a current ratio of 1.57, a quick ratio of 0.74 and a debt-to-equity ratio of 1.13. The company has a market cap of $5.77 billion, a P/E ratio of 73.23, a P/E/G ratio of 2.58 and a beta of 1.16. Bruker has a twelve month low of $34.10 and a twelve month high of $72.94.

Bruker (NASDAQ:BRKRGet Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.01. The firm had revenue of $801.40 million for the quarter, compared to the consensus estimate of $763.83 million. Bruker had a net margin of 2.31% and a return on equity of 19.47%. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. During the same period last year, the firm posted $0.53 earnings per share. On average, sell-side analysts forecast that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Monday, June 16th will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.53%. The ex-dividend date is Monday, June 16th. Bruker’s dividend payout ratio (DPR) is presently 38.46%.

About Bruker

(Get Free Report

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Recommended Stories

Analyst Recommendations for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.